New Consensus Statements Recommend MRI and MRI-Targeted Biopsies for Monitoring Prostate Cancer After Negative Biopsy

New Consensus Statements Recommend MRI and MRI-Targeted Biopsies for Monitoring Prostate Cancer After Negative Biopsy
An expert panel of urologists and radiologists from the American Urological Association (AUA) and the Society of Abdominal Radiology (SAR) has issued a set of consensus statements indicating that MRI (magnetic resonance imaging)-targeted biopsies could be used to monitor patients with negative biopsy for prostate cancer. The consensus statements were published in the Journal of Urology and include detailed literature upon which the panel's recommendations are based. Prostate MRI is a technology that helps in the identification of patients with previous negative biopsies who might require repeat biopsies. The MRI works by identifying areas of interest to target and direct biopsies, as well as to help direct biopsies to these areas that need image guidance. The debate around the issue questions if these patients should be monitored at all, and if they should, then how should health care providers deal with the concerns about over-detection, over-treatment and under-detection due to sampling errors in biopsies. In answer to the questions around the issue, the panel recommends that prostate MRI and MRI-targeted biopsies be used for any patients in whom prostate cancer is suspected, even if they have had a negative biopsy, or for those considering a possible repeat biopsy. A decision to perform an MRI also should take into account the results of any other biomarkers and he cost of the examination, the panel recommended. "The panel recognized a role for prostate MRI and MRI-targeted biopsy to increase the detection of clinically significant p
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *